{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:44:45Z","timestamp":1773470685295,"version":"3.50.1"},"reference-count":316,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"FWF project","doi-asserted-by":"publisher","award":["T942"],"award-info":[{"award-number":["T942"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Pesticides are essential in agriculture for protecting crops and boosting productivity, but their widespread use may pose significant health risks. Farmworkers face direct exposure through skin contact and inhalation, which may lead to hormonal imbalances, neurological disorders, and elevated cancer risks. Moreover, pesticide residues in food and water may affect surrounding communities. One of the lesser investigated issues is immunotoxicity, mostly because the chronic effects of compound exposure are very complex to study. As a case study, this work utilized pharmacophore modeling and virtual screening to identify pesticides that may inhibit Janus kinases (JAK1, JAK2, JAK3) and tyrosine kinase 2 (TYK2), which are pivotal in immune response regulation, and are associated with cancer development and increased infection susceptibility. We identified 64 potential pesticide candidates, 22 of which have previously been detected in the human body, as confirmed by the Human Metabolome Database. These results underscore the critical need for further research into potential immunotoxic and chronic impacts of the respective pesticides on human health.<\/jats:p>","DOI":"10.3390\/molecules30102183","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:57:28Z","timestamp":1747378648000},"page":"2183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0752-0023","authenticated-orcid":false,"given":"Florian","family":"Fischer","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Research and Innovation Center for Regenerative Medicine and Novel Therapies, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7662-9882","authenticated-orcid":false,"given":"Veronika","family":"Temml","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Research and Innovation Center for Regenerative Medicine and Novel Therapies, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9933-8938","authenticated-orcid":false,"given":"Daniela","family":"Schuster","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Research and Innovation Center for Regenerative Medicine and Novel Therapies, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.shaw.2013.07.004","article-title":"Dermal exposure associated with occupational end use of pesticides and the role of protective measures","volume":"4","author":"Macfarlane","year":"2013","journal-title":"Saf. Health Work"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cortex.2015.09.006","article-title":"Pesticide poisoning and neurobehavioral function among farm workers in Jiangsu, People\u2019s Republic of China","volume":"74","author":"Zhang","year":"2016","journal-title":"Cortex"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.envres.2016.05.011","article-title":"Chlorpyrifos exposure in farmers and urban adults: Metabolic characteristic, exposure estimation, and potential effect of oxidative damage","volume":"149","author":"Wang","year":"2016","journal-title":"Environ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Damalas, C.A., and Koutroubas, S.D. (2016). Farmers\u2019 Exposure to Pesticides: Toxicity Types and Ways of Prevention. Toxics, 4.","DOI":"10.3390\/toxics4010001"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.scitotenv.2016.09.009","article-title":"Exposure to pesticides and the associated human health effects","volume":"575","author":"Kim","year":"2017","journal-title":"Sci. Total Environ."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Syafrudin, M., Kristanti, R.A., Yuniarto, A., Hadibarata, T., Rhee, J., Al-Onazi, W.A., Algarni, T.S., Almarri, A.H., and Al-Mohaimeed, A.M. (2021). Pesticides in Drinking Water\u2014A Review. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18020468"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113359","DOI":"10.1016\/j.fct.2022.113359","article-title":"Cumulative dietary risk assessment of pesticides in food for the Danish population for the period 2012\u20132017","volume":"168","author":"Jensen","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fucic, A., Duca, R.C., Galea, K.S., Maric, T., Garcia, K., Bloom, M.S., Andersen, H.R., and Vena, J.E. (2021). Reproductive Health Risks Associated with Occupational and Environmental Exposure to Pesticides. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18126576"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00401-019-02033-9","article-title":"Neurotoxicity of pesticides","volume":"138","author":"Richardson","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3322\/caac.21170","article-title":"Increased cancer burden among pesticide applicators and others due to pesticide exposure","volume":"63","author":"Alavanja","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ijc.22258","article-title":"Occupational exposure to organochlorine insecticides and cancer incidence in the Agricultural Health Study","volume":"120","author":"Purdue","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1289\/ehp.9301","article-title":"Fonofos exposure and cancer incidence in the agricultural health study","volume":"114","author":"Mahajan","year":"2006","journal-title":"Environ. Health Perspect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/15376516.2015.1020182","article-title":"A comprehensive review of pesticides and the immune dysregulation: Mechanisms, evidence and consequences","volume":"25","author":"Mokarizadeh","year":"2015","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.etap.2013.07.004","article-title":"Cytokine patterns in greenhouse workers occupationally exposed to \u03b1-cypermethrin: An observational study","volume":"36","author":"Costa","year":"2013","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41232-022-00221-x","article-title":"Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases\u2014RA as a role model","volume":"42","author":"Takeuchi","year":"2022","journal-title":"Inflamm. Regen."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: From basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hoisnard, L., Lebrun-Vignes, B., Maury, S., Mahevas, M., El Karoui, K., Roy, L., Zarour, A., Michel, M., Cohen, J.L., and Amiot, A. (2022). Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-10777-w"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Giordano, D., Biancaniello, C., Argenio, M.A., and Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050646"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1351\/pac199870051129","article-title":"Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)","volume":"70","author":"Wermuth","year":"1998","journal-title":"Pure Appl. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"22799","DOI":"10.3390\/molecules201219880","article-title":"Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases","volume":"20","author":"Kaserer","year":"2015","journal-title":"Molecules"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2174\/138161210791164072","article-title":"Identification of bioactive natural products by pharmacophore-based virtual screening","volume":"16","author":"Schuster","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bmcl.2016.02.035","article-title":"Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors","volume":"26","author":"Simov","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1016\/j.bmc.2016.08.007","article-title":"Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3","volume":"24","author":"Nakajima","year":"2016","journal-title":"Bioorganic Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1021\/acsmedchemlett.8b00508","article-title":"Discovery of a JAK1\/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis","volume":"10","author":"Spergel","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/acs.jmedchem.0c01467","article-title":"Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections","volume":"65","author":"Raghuvanshi","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_30","unstructured":"Mesaros, E.F., Dugan, B.J., Dorsey, B.D., Milkiewicz, K.L., Curry, M.A., and Gingrich, D.E. (2009). Preparation and Uses of 1,2,4-triazolo [1,5a] Pyridine Derivatives. (8633173-B2), U.S. Patent."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1021\/acsmedchemlett.0c00015","article-title":"Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma","volume":"11","author":"Mathison","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.bmc.2019.02.054","article-title":"Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold","volume":"27","author":"Yin","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.bmcl.2016.02.003","article-title":"Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties","volume":"26","author":"Sloman","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ma, X., Diao, Y., Ge, H., Xu, F., Zhu, L., Zhao, Z., and Li, H. (2020). Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors. Bioorganic Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.127048"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of Selective Covalent Janus Kinase 3 Inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1016\/j.bmcl.2017.09.029","article-title":"Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors","volume":"27","author":"Bhide","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fensome, A., Ambler, C.M., Arnold, E., Banker, M.E., Clark, J.D., Dowty, M.E., Efremov, I.V., Flick, A., Gerstenberger, B.S., and Gifford, R.S. (2020). Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. Bioorganic Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115481"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/jm501929n","article-title":"Development of novel ACK1\/TNK2 inhibitors using a fragment-based approach","volume":"58","author":"Lawrence","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: From hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_40","unstructured":"Bauer, S.M., and Pandey, A. (2024, December 16). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9868729-B2, Inhibitors of Protein Kinases. United States, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9868729-B2."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106885","DOI":"10.1016\/j.envint.2021.106885","article-title":"Discovering pesticides and their TPs in Luxembourg waters using open cheminformatics approaches","volume":"158","author":"Krier","year":"2022","journal-title":"Environ. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","article-title":"HMDB 5.0: The Human Metabolome Database for 2022","volume":"50","author":"Wishart","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cbpa.2006.04.002","article-title":"Structure-based virtual screening of chemical libraries for drug discovery","volume":"10","author":"Ghosh","year":"2006","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2174\/092986708784049630","article-title":"Pharmacophore-based virtual screening","volume":"15","author":"Sun","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhang, J., Li, W., Gong, M., Gu, Y., Zhang, H., Dong, B., Guo, Q., Pang, X., Xiang, Q., and He, X. (2023). Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: A systematic review and meta-analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1189389"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1017\/err.2020.18","article-title":"Achieving a High Level of Protection from Pesticides in Europe: Problems with the Current Risk Assessment Procedure and Solutions","volume":"11","author":"Robinson","year":"2020","journal-title":"Eur. J. Risk Regul."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gerken, J., Vincent, G.T., Zapata, D., Barron, I.G., and Zapata, I. (2024). Comprehensive assessment of pesticide use patterns and increased cancer risk. Front. Cancer Control Soc., 2.","DOI":"10.3389\/fcacs.2024.1368086"},{"key":"ref_51","first-page":"28","article-title":"Mepanipyrim (Pesticides)","volume":"4","author":"Yamazoe","year":"2016","journal-title":"Food Saf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.1007\/s00216-024-05590-5","article-title":"Perfluoroalkyl acid precursor or weakly fluorinated organic compound? A proof of concept for oxidative fractionation of PFAS and organofluorines","volume":"416","author":"Zweigle","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109420","DOI":"10.1016\/j.ecoenv.2019.109420","article-title":"Immunomodulatory effect of mancozeb, chlorothalonil, and thiophanate methyl pesticides on macrophage cells","volume":"182","author":"Weis","year":"2019","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1021\/jf050767g","article-title":"Partitioning of penoxsulam, a new sulfonamide herbicide","volume":"53","author":"Jabusch","year":"2005","journal-title":"J. Agric. Food Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.envint.2020.105955","article-title":"Residential proximity to agriculture and risk of childhood leukemia and central nervous system tumors in the Danish national birth cohort","volume":"143","author":"Patel","year":"2020","journal-title":"Environ. Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e24431","DOI":"10.1016\/j.heliyon.2024.e24431","article-title":"Influence of triazines and lipopolysaccharide coexposure on inflammatory response and histopathological changes in the testis and liver of BalB\/c mice","volume":"10","author":"Abarikwu","year":"2024","journal-title":"Heliyon"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1289\/ehp.0800096","article-title":"The synergistic toxicity of pesticide mixtures: Implications for risk assessment and the conservation of endangered Pacific salmon","volume":"117","author":"Laetz","year":"2009","journal-title":"Environ. Health Perspect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: A large-scale bioactivity database for drug discovery","volume":"40","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.1016\/j.bmcl.2012.10.008","article-title":"Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2","volume":"22","author":"Labadie","year":"2012","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","article-title":"Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor","volume":"63","author":"Su","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1021\/acs.jmedchem.7b01135","article-title":"The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties","volume":"60","author":"Siu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.chembiol.2023.05.007","article-title":"New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation","volume":"30","author":"Arwood","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.bmcl.2013.03.015","article-title":"Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors","volume":"23","author":"Hermann","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/S0960-894X(03)00657-7","article-title":"Mapping the kinase domain of janus kinase 3","volume":"13","author":"Adams","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1016\/j.bmcl.2009.08.071","article-title":"Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)","volume":"19","author":"Burns","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1016\/j.bmcl.2009.09.080","article-title":"2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors","volume":"19","author":"Cole","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.bmcl.2010.01.069","article-title":"2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors","volume":"20","author":"Gerspacher","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.bmcl.2010.01.069","article-title":"Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors","volume":"20","author":"Gerspacher","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.bmcl.2010.03.015","article-title":"Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases","volume":"20","author":"Fidanze","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acsmedchemlett.8b00081","article-title":"Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift","volume":"9","author":"Dart","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_76","unstructured":"(2025, February 25). National Center for Biotechnology Information (2024). PubChem Bioassay Record for AID 1699, S.T.S.R.I.M.S.C.R.D., 2024, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/1699."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"112155","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1016\/j.bmcl.2010.08.140","article-title":"Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors","volume":"20","author":"Belanger","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1016\/j.bmcl.2010.10.031","article-title":"The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: Hit to lead","volume":"20","author":"Siu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.bmcl.2003.08.054","article-title":"Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck)","volume":"13","author":"Wityak","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_81","unstructured":"Ma, H., Filip, S.V., Stent, M.A.H., Dolan, J.A., and Dietrich, B. (2013). JAK3 Inhibitors for the Treatment of Autoimmune and Inflammatory Disorders. (8592415-B2), U.S. Patent."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/ml100146z","article-title":"Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway","volume":"1","author":"Ren","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/jm1011319","article-title":"Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak\/Stat pathway","volume":"54","author":"Ioannidis","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bmcl.2014.01.001","article-title":"Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors","volume":"24","author":"McDonnell","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.bmcl.2011.01.022","article-title":"Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3","volume":"21","author":"Harikrishnan","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bmc.2011.01.067","article-title":"Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells","volume":"19","author":"Kim","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/ml100136n","article-title":"Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery","volume":"1","author":"Medina","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1016\/j.bmcl.2011.03.053","article-title":"In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors","volume":"21","author":"Wang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.bmcl.2011.04.060","article-title":"Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant","volume":"21","author":"Thomas","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"112148","DOI":"10.1016\/j.ejmech.2020.112148","article-title":"Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors","volume":"191","author":"Shu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers","volume":"66","author":"Qiu","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1021\/jm200909u","article-title":"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders","volume":"54","author":"Lim","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.bmcl.2010.07.001","article-title":"Synthesis of N-aryl-3-(indol-3-yl)propanamides and their immunosuppressive activities","volume":"20","author":"Giraud","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1021\/jm400798j","article-title":"Selectivity data: Assessment, predictions, concordance, and implications","volume":"56","author":"Gao","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1021\/acs.jmedchem.0c00192","article-title":"Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core","volume":"63","author":"Liosi","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bmcl.2011.11.006","article-title":"Structure-based design of PDK1 inhibitors","volume":"22","author":"Poulsen","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bmcl.2011.11.049","article-title":"Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases","volume":"22","author":"Zificsak","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8440","DOI":"10.1021\/jm200911r","article-title":"Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors","volume":"54","author":"Schenkel","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","article-title":"Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy","volume":"59","author":"Sonawane","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/jm201112g","article-title":"Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317\/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer","volume":"55","author":"William","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug Discovery Targeting Bromodomain-Containing Protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1016\/j.bmcl.2016.09.077","article-title":"Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors","volume":"26","author":"Hoemann","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.bmcl.2012.01.043","article-title":"Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors","volume":"22","author":"Oza","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1021\/acs.jmedchem.6b00157","article-title":"Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/jm300248q","article-title":"A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: Discovery of CEP-33779","volume":"55","author":"Dugan","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_108","unstructured":"Mitton-Fry, M.J., Berlinski, P.J., Birchmeier, M.J., Bowman, J.W., Gonzales, A.J., Kamerling, S.G., and Mann, D.W. (2015). Pyrrolo[2,3-d]pyrimidine Compounds. (US-9161939-B2), U.S. Patent."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.5b01857","article-title":"Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors","volume":"59","author":"Yogo","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1021\/acs.jmedchem.5b01263","article-title":"Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors","volume":"58","author":"Kim","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/jm800662z","article-title":"Virtual screening to successfully identify novel janus kinase 3 inhibitors: A sequential focused screening approach","volume":"51","author":"Chen","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1073\/pnas.0708800104","article-title":"A systematic interaction map of validated kinase inhibitors with Ser\/Thr kinases","volume":"104","author":"Fedorov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/jm0605482","article-title":"Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: Synthesis, SAR, and in vivo anti-inflammatory activity","volume":"49","author":"DiMauro","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1021\/ml300074j","article-title":"Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors","volume":"3","author":"Wang","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"112498","DOI":"10.1016\/j.ejmech.2020.112498","article-title":"Recent researches for dual Aurora target inhibitors in antitumor field","volume":"203","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1021\/jm300334d","article-title":"Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors","volume":"55","author":"Lawrence","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1021\/jm3012239","article-title":"Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors","volume":"55","author":"Hanan","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1021\/jm200326p","article-title":"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2\/fms-like tyrosine kinase-3 (JAK2\/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma","volume":"54","author":"William","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1016\/j.bmcl.2012.10.007","article-title":"SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors","volume":"22","author":"Forsyth","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1016\/j.bmcl.2006.08.022","article-title":"Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3","volume":"16","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.bmc.2016.04.030","article-title":"Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors","volume":"24","author":"Liang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bmc.2019.03.009","article-title":"Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors","volume":"27","author":"Yu","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10440","DOI":"10.1021\/acs.jmedchem.8b00510","article-title":"Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series","volume":"61","author":"Elsayed","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bmc.2006.10.050","article-title":"Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK)","volume":"15","author":"Uckun","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bmcl.2012.11.108","article-title":"Design and synthesis of tricyclic cores for kinase inhibition","volume":"23","author":"Fiamengo","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/jm301646k","article-title":"3-Amido pyrrolopyrazine JAK kinase inhibitors: Development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models","volume":"56","author":"Soth","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bmcl.2006.10.062","article-title":"Simplified staurosporine analogs as potent JAK3 inhibitors","volume":"17","author":"Yang","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.bmcl.2013.02.012","article-title":"Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome","volume":"23","author":"Lynch","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/j.bmcl.2013.02.111","article-title":"Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target","volume":"23","author":"Guan","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","article-title":"Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials","volume":"56","author":"Marsilje","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.bmcl.2007.01.048","article-title":"Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties","volume":"17","author":"Martin","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.bmcl.2013.06.008","article-title":"2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors","volume":"23","author":"Siu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1016\/j.bmc.2013.09.018","article-title":"Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)","volume":"21","author":"Brasca","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bmcl.2007.01.057","article-title":"Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR","volume":"17","author":"DiMauro","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.bmcl.2007.10.033","article-title":"Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors","volume":"17","author":"Boulet","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.bmcl.2014.05.080","article-title":"Synthesis and structure-activity relationships of 4-fluorophenyl-imidazole p38\u03b1 MAPK, CK1\u03b4 and JAK2 kinase inhibitors","volume":"24","author":"Seerden","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1016\/j.bmcl.2013.08.009","article-title":"Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics","volume":"23","author":"Zhao","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1021\/jm401546n","article-title":"Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors","volume":"57","author":"Su","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.bmcl.2014.02.011","article-title":"The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: Lead optimization","volume":"24","author":"Siu","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/jm401805h","article-title":"Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib","volume":"57","author":"Huang","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"114551","DOI":"10.1016\/j.ejmech.2022.114551","article-title":"Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases","volume":"239","author":"Shen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"113573","DOI":"10.1016\/j.ejmech.2021.113573","article-title":"Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities","volume":"222","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.bmcl.2014.02.064","article-title":"Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasms","volume":"24","author":"Haidle","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.bmcl.2014.01.058","article-title":"2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors","volume":"24","author":"Costales","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/acs.jmedchem.0c01026","article-title":"Discovery and Biological Evaluation of","volume":"64","author":"Park","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Ren, J., Shi, W., Zhao, D., Wang, Q., Chang, X., He, X., Wang, X., Gao, Y., Lu, P., and Zhang, X. (2020). Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2019.115236"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1016\/j.bmc.2014.06.025","article-title":"Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors","volume":"22","author":"Brasca","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1021\/jm501578n","article-title":"Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation","volume":"57","author":"Hanan","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1021\/ml500242y","article-title":"Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation","volume":"6","author":"Goodwin","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1016\/j.bmcl.2014.10.061","article-title":"Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors","volume":"24","author":"Duan","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.bmc.2015.03.059","article-title":"Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders","volume":"23","author":"Brasca","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/acsmedchemlett.5b00226","article-title":"Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms","volume":"6","author":"Wan","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.bmcl.2015.04.101","article-title":"9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors","volume":"25","author":"Zimmermann","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1016\/j.bmc.2015.05.028","article-title":"Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors","volume":"23","author":"Yamagishi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1016\/j.bmc.2015.05.034","article-title":"Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3","volume":"23","author":"Nakajima","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1016\/j.bmcl.2015.07.037","article-title":"Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design","volume":"25","author":"Jang","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1016\/j.bmcl.2015.07.102","article-title":"Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton\u2019s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)","volume":"25","author":"Liu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1021\/acsmedchemlett.5b00225","article-title":"Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors","volume":"6","author":"Hart","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_162","unstructured":"(2025, February 25). ChEMBL Database, EMBL-EBI (2024). ChEMBL Document: Affinity Phenotypic Cellular Literature for EUbOPEN Chemogenomic Library (CHEMBL5444388)-ChEMBL(20 January 2022). Available online: https:\/\/www.ebi.ac.uk\/chembl\/explore\/document\/CHEMBL5444388."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1016\/j.bmcl.2015.09.011","article-title":"Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors","volume":"25","author":"Choi","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_164","unstructured":"Curry, M.A., Dorsey, B.D., Dugan, B.J., Gingrich, D.E., Mesaros, E.F., and Milkiewicz, K.L. (2014). Preparation and Uses of 1,2,4-triazolo[1,5a]pyridine Derivatives. (US-8633173-B2), U.S. Patent."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin","volume":"60","author":"Jones","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acs.jmedchem.8b01308","article-title":"Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors","volume":"61","author":"Trujillo","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_167","unstructured":"Bauer, S.M., Jia, Z.J., Mehrotra, M., Song, Y., Xu, Q., Huang, W., Venkataramani, C., Rose, J.W., and Pandey, A. (2013). Inhibitors of Syk and\/or JAK Kinase. (US-8501944-B2), U.S. Patent."},{"key":"ref_168","unstructured":"Purandare, A.V., Batt, D.G., Liu, Q., Johnson, W.L., Mastalerz, H., Zhang, G., and Zimmermann, K. (2014). Carbazole and Carboline Kinase Inhibitors. (US-8815840-B2), U.S. Patent."},{"key":"ref_169","unstructured":"Woo, H.C., Cash, B., Ahearn, S.P., Dinsmore, C., Jung, J., Pu, Q., Rivkin, A., Scott, M.E., Witter, D.J., and Woo, H.C. (2015). Pyrrolopyrimidines as Janus Kinase Inhibitors. (US-8993756-B2), U.S. Patent."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.bmcl.2017.07.079","article-title":"Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting","volume":"27","author":"Forster","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_171","unstructured":"Promo, M.A., Xie, J., Acker, B.A., Hartmann, S.J., Wolfson, S.G., Huang, H.-C., and Jacobsen, E.J. (2014). Pyrrolo[2,3-d]pyrimidine Compounds as Janus Kinase Inhibitors. (US-8633206-B2), U.S. Patent."},{"key":"ref_172","unstructured":"Brown, M.F., Fenwick, A.E., Flanagan, M.E., Gonzales, A., Johnson, T.A., Kaila, N., Mitton-Fry, M.J., Strohbach, J.W., TenBrink, R.E., and Trzupek, J.D. (2015). Pyrrolo[2,3-D]pyrimidine Derivatives. (US-9035074-B2), U.S. Patent."},{"key":"ref_173","unstructured":"McAllister, A., Murone, M., Sengupta, S., and Shetty, S.J. (2013). Bicyclic Compounds and Their Uses as Dual c-SRC\/JAK Inhibitors. (US-8440679-B2), U.S. Patent."},{"key":"ref_174","unstructured":"Davies, A., Ioannidis, S., Lamb, M., Su, M., Wang, T., and Zhang, H. (2013). 9-(Pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl)-3H-imidazo[4,5-B] Pyridin-5-Amine Derivatives and Their Use for the Treatment of Cancer. (US8486966B2), U.S. Patent."},{"key":"ref_175","unstructured":"De Vicente Fidalgo, J., Hermann, J.C., Lemoine, R., Li, H., and Lovey, A.J. (2013). Inhibitors of JAK for the Treatment of Autoimmune and Inflammatory Diseases. (US-8618103-B2), U.S. Patent, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-8618103-B2."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.bmcl.2017.05.043","article-title":"Discovery of potent and efficacious pyrrolopyridazines as dual JAK1\/3 inhibitors","volume":"27","author":"Hynes","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_177","unstructured":"Wrobleski, S.T., Brown, G.D., Doweyko, L.M., Duan, J., and Guo, J. (2014). Pyrrolopyridazine JAK3 Inhibitors and Their Use for the Treatment of Inflammatory and Autoimmune Diseases. (US-8921368-B2), U.S. Patent."},{"key":"ref_178","unstructured":"Allen, S., Andrews, S.W., Condroski, K.R., Haas, J., and Huang, L. (2014). Substituted Pyrazolo[1,5-a]pyrimidine Compounds as Trk Kinase Inhibitors. (US-8791123-B2), U.S. Patent."},{"key":"ref_179","unstructured":"Noji, S., Shiozaki, M., Miura, T., Hara, Y., Yamanaka, H., Maeda, K., Hori, A., Inoue, M., and Hase, Y. (2013). Nitrogen-Containing Spirocyclic Compounds and Pharmaceutical Uses Thereof. (US-8609647-B2), U.S. Patent."},{"key":"ref_180","unstructured":"Combs, A.P., Sparks, R.B., Yue, E.W.T., Feng, H., and Bower, M.J. (2014). Macrocyclic Compounds and Their Use as Kinase Inhibitors. (US8765727B2), U.S. Patent."},{"key":"ref_181","unstructured":"Brubaker, J., Close, J.T., Jung, J., Martinez, M., and White, C. (2016). Acyclic Cyanoethylpyrazoles as Janus Kinase Inhibitors. (US9493441B2), U.S. Patent."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1021\/acs.jmedchem.0c00359","article-title":"Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bmcl.2015.11.031","article-title":"Identification of azabenzimidazoles as potent JAK1 selective inhibitors","volume":"26","author":"Vasbinder","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bmcl.2016.02.074","article-title":"Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors","volume":"26","author":"Stauffer","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.bmcl.2016.04.027","article-title":"Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors","volume":"26","author":"Wang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1016\/j.bmcl.2016.05.078","article-title":"Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability","volume":"26","author":"Kim","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/jm061112p","article-title":"Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase","volume":"50","author":"Cee","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1021\/jm060435i","article-title":"Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: Synthesis, SAR, and in vivo antiinflammatory activity","volume":"49","author":"Martin","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ejmech.2016.08.055","article-title":"Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors","volume":"124","author":"Phuangsawai","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bmc.2018.02.022","article-title":"Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors","volume":"26","author":"Hou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejmech.2018.10.052","article-title":"ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil\/oxaliplatin resistant and stem cells","volume":"161","author":"Narayan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_192","unstructured":"Vankayalapati, H., Yerramreddy, V.K., Gangireddy, P., and Appalaneni, R.P. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9206188-B2, Substituted Pyrrolo[2,3-b]pyridines as ITK and JAK Inhibitors. United States, 8 December 2015, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9206188-B2."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bmc.2016.10.011","article-title":"Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors","volume":"25","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_194","unstructured":"Batt, D.G., Bertrand, M.B., Delucca, G., Galella, M.A., and Ko, S.S. (2025, February 25). Substituted Tetrahydrocarbazole and Carbazole Carboxamide Compounds. United States Patent US-9334290-B2, 10 May 2016. Assignee: Bristol Myers Squibb Co. Available online: https:\/\/patents.google.com\/patent\/US9334290B2."},{"key":"ref_195","unstructured":"Hayashi, K., Watanabe, T., Toyama, K., Kamon, J., and Minami, M. (2025, February 25). Substituted Pyrrolo[2,3-h][1,6]naphthyridines and Compositions Thereof as JAK Inhibitors. United States Patent US-9216999-B2, 22 December 2015. Available online: https:\/\/patents.google.com\/patent\/US9216999B2."},{"key":"ref_196","unstructured":"Yang, B.V., Brown, G.D., Gupta, A.K., and Pitts, W.J. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9428511-B2, Imidazopyridazine JAK3 Inhibitors and Their Use for the Treatment of Inflammatory and Autoimmune Diseases. United States. 30 August 2016, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9428511-B2."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1021\/acs.jmedchem.6b00597","article-title":"Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening","volume":"59","author":"Czodrowski","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bmcl.2006.12.018","article-title":"Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)","volume":"17","author":"Clark","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_199","unstructured":"Mitton-Fry, M.J., Berlinski, P.J., Birchmeier, M.J., Bowman, J.W., and Gonzales, A.J. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9161939-B2, Pyrrolo[2,3-d]pyrimidine compounds. United States. 20 October 2015, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9161939-B2."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family","volume":"59","author":"Smaill","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_201","unstructured":"Huang, T., Xue, C.-B., Li, H.-Y., and Li, Q. (2014). Piperidin-4-yl Azetidine Derivatives as JAK1 Inhibitors. (US-8765734-B2), U.S. Patent, Available online: https:\/\/patents.google.com\/patent\/US8765734B2."},{"key":"ref_202","unstructured":"Takahashi, K., Watanabe, T., Hayashi, K., Kurihara, K., Nakamura, T., Yamamoto, A., Nishimura, T., Kamiyama, T., and Hidaka, Y. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9475813-B2, Tricyclic Pyrrolopyridine Compound, and JAK Inhibitor. United States. 25 October 2016, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9475813-B2."},{"key":"ref_203","unstructured":"Xi, N., Li, M., Hu, H., and Dai, W. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9403801-B2, Substituted Heteroaryl Compounds and Methods of Use. United States. 2 August 2016, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9403801-B2."},{"key":"ref_204","unstructured":"Goldstein, D.M., Brameld, K.A., and Verner, E. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9187487-B2, Azaindole Derivatives as Tyrosine Kinase Inhibitors. United States. 17 November 2015, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9187487-B2."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/acsmedchemlett.6b00235","article-title":"Discovery of Novel Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold","volume":"7","author":"Ge","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_206","unstructured":"Li, Y.-L., and Rodgers, J.D. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9216984-B2, 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile and Heptanenitrile as JAK Inhibitors. United States. 22 December 2015, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9216984-B2."},{"key":"ref_207","unstructured":"Su, W.-G., Deng, W., Li, J., and Ji, J. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9346810-B2, Pyrrolopyrimidine Compounds and Uses Thereof. United States. 24 May 2016, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9346810-B2."},{"key":"ref_208","unstructured":"Brubaker, J., Childers, M.L., Christopher, M., Close, J.T., and Katz, J.D. (2025, February 25). National Center for Biotechnology Information (2024). PubChem Patent Summary for US-9328099-B2, Cyanomethylpyrazole Carboxamides as Janus kinase Inhibitors. United States. 3 May 2016, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9328099-B2."},{"key":"ref_209","unstructured":"Reddy, E.P., and Reddy, M.V.R. (2014). Substituted Pyrido[2,3-d]pyrimidin-7(8H)-ones and Therapeutic Uses Thereof. (US8889696B2)."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1016\/j.bmcl.2016.10.087","article-title":"Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)","volume":"26","author":"Lam","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acsmedchemlett.9b00621","article-title":"Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases","volume":"11","author":"Blomgren","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1021\/acsmedchemlett.7b00209","article-title":"Janus-Associated Kinase 1 (JAK1) Inhibitors as Potential Treatment for Immune Disorders","volume":"8","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1016\/j.bmcl.2017.09.023","article-title":"Discovery of highly potent, selective, covalent inhibitors of JAK3","volume":"27","author":"Kempson","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1021\/acs.jmedchem.0c00093","article-title":"Monomeric Targeted Protein Degraders","volume":"63","author":"Hanan","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1021\/acs.jmedchem.7b00360","article-title":"Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors","volume":"60","author":"Brameld","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_216","unstructured":"(2023, February 02). Data for DCP Probe TP-030-2. Available online: https:\/\/www.ebi.ac.uk\/chembl\/explore\/document\/CHEMBL4507326."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1021\/acs.jmedchem.7b00678","article-title":"Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat","volume":"60","author":"Yao","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.bmcl.2017.04.053","article-title":"Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors","volume":"27","author":"Fischer","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_220","unstructured":"Brubaker, J., Close, J., Siu, T., Smith, G.F., and Torres, L.E. (2016). Pyrazole Carboxamides as Janus Kinase Inhibitors. (US9394282B2), U.S. Patent."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"9811","DOI":"10.1021\/acs.jmedchem.8b00294","article-title":"Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction","volume":"61","author":"Aubert","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections","volume":"61","author":"Huang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/acs.jmedchem.8b00076","article-title":"Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors","volume":"61","author":"Grimster","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bmc.2018.01.021","article-title":"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor","volume":"26","author":"Chough","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bmcl.2018.02.037","article-title":"Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor","volume":"28","author":"Yu","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1021\/acs.jmedchem.7b00873","article-title":"Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors","volume":"61","author":"Hamad","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.bmc.2019.03.048","article-title":"Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors","volume":"27","author":"Wang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Zheng, J., Wu, J., Ding, X., Shen, H.C., and Zou, G. (2021). Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorg. Med. Chem. Lett., 38.","DOI":"10.1016\/j.bmcl.2021.127862"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.bmcl.2018.06.037","article-title":"Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)","volume":"28","author":"Yao","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.bmcl.2018.07.041","article-title":"Conversion of carbazole carboxamide based reversible inhibitors of Bruton\u2019s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series","volume":"28","author":"Liu","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1039\/C8MD00068A","article-title":"N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK","volume":"9","author":"Pippione","year":"2018","journal-title":"Medchemcomm"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2017.12.003","article-title":"A highly potent CDK4\/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy","volume":"144","author":"Yin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C7MD00568G","article-title":"Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor","volume":"9","author":"Chough","year":"2018","journal-title":"Medchemcomm"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejmech.2018.09.024","article-title":"Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat","volume":"158","author":"Mustafa","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/acs.jmedchem.2c01800","article-title":"Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1021\/acs.jmedchem.3c00926","article-title":"Progress on the Pharmacological Targeting of Janus Pseudokinases","volume":"66","author":"Henry","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.ejmech.2017.10.080","article-title":"Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma","volume":"143","author":"Ge","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1039\/C6MD00560H","article-title":"Identification of imidazo[1,2-","volume":"8","author":"Moslin","year":"2017","journal-title":"Medchemcomm"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1021\/acs.jmedchem.0c00450","article-title":"Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders","volume":"63","author":"Noji","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"111590","DOI":"10.1016\/j.ejmech.2019.111590","article-title":"Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3","volume":"181","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_241","unstructured":"(2023, July 02). EUbOPEN. Selectivity Literature for EUbOPEN Chemogenomic Library. Available online: https:\/\/www.ebi.ac.uk\/chembl\/explore\/document\/CHEMBL5465560."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.04.053","article-title":"Targeting tropomyosin receptor kinase for cancer therapy","volume":"175","author":"Miao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1021\/acs.jmedchem.9b00443","article-title":"Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)","volume":"62","author":"Moslin","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1021\/acs.jmedchem.8b00667","article-title":"Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances","volume":"61","author":"Bryan","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.jmedchem.0c01468","article-title":"Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2019.06.005","article-title":"Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4\/6 inhibitor for treatment of cancer","volume":"178","author":"Shi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1021\/acs.jmedchem.8b01597","article-title":"Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1021\/acsmedchemlett.6b00247","article-title":"Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors","volume":"7","author":"Liang","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/acs.jmedchem.9b00533","article-title":"Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases","volume":"62","author":"Bach","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejmech.2019.03.055","article-title":"Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk)","volume":"173","author":"Tang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_251","unstructured":"CoE, J.W., Dehnhardt, C.M., Jones, P., Korturn, S.W., Sabnis, Y.A., Wakenhut, F.M., and Whitlock, G.A. (2014). JAK Inhibitors for the Treatment of Inflammatory Diseases. (US8895544B2), U.S. Patent."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1016\/j.bmcl.2016.08.070","article-title":"Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors","volume":"26","author":"Garton","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.jmedchem.9b01439","article-title":"Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease","volume":"63","author":"Leonard","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acs.jmedchem.8b01823","article-title":"Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor","volume":"62","author":"Shi","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_255","unstructured":"National Center for Biotechnology Information (2024, December 18). PubChem Substance Record for SID 395763535, S., Source: PATENTSCOPE (WIPO), Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/substance\/395763535."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejmech.2018.11.072","article-title":"Targeting the immunity protein kinases for immuno-oncology","volume":"163","author":"Yuan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1021\/acsmedchemlett.6b00087","article-title":"Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors","volume":"7","author":"Dack","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1016\/j.bmcl.2004.09.093","article-title":"Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors","volume":"14","author":"Chen","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"10305","DOI":"10.1021\/acs.jmedchem.9b01348","article-title":"Discovery of Potent and Orally Effective Dual Janus Kinase 2\/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_261","unstructured":"National Center for Biotechnology Information (2024, December 25). PubChem Bioassay Record for AID 1791642, N.S.F.J., Source: ChEMBL, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/1791642."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1016\/j.bmc.2016.08.008","article-title":"The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3","volume":"24","author":"Lee","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Luo, Z., Wang, L., Fu, Z., Shuai, B., Luo, M., Hu, G., Chen, J., Sun, J., Wang, J., and Li, J. (2021). Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorg. Med. Chem. Lett., 47.","DOI":"10.1016\/j.bmcl.2021.128149"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bmc.2019.02.029","article-title":"The impact of binding site waters on the activity\/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors","volume":"27","author":"Egyed","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1021\/acsmedchemlett.2c00411","article-title":"Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate","volume":"13","author":"Chen","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/jm201331s","article-title":"Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series","volume":"55","author":"Liu","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1016\/j.bmcl.2008.10.039","article-title":"Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity","volume":"18","author":"Schlapbach","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1016\/j.bmcl.2008.07.080","article-title":"Evaluation of indazole-based compounds as a new class of potent KDR\/VEGFR-2 inhibitors","volume":"18","author":"Bauer","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Zhou, H., McGowan, M.A., Lipford, K., Christopher, M., Fradera, X., Witter, D., Lesburg, C.A., Li, C., Methot, J.L., and Lampe, J. (2020). Discovery and optimization of heteroaryl piperazines as potent and selective PI3K\u03b4 inhibitors. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2019.126715"},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Shah, R.R., Redmond, J.M., Mihut, A., Menon, M., Evans, J.P., Murphy, J.A., Bartholomew, M.A., and Coe, D.M. (2020). Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115326"},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Zheng, X., Wang, C., Sun, X., Sun, H., Ma, T., Li, Y., Liu, K., Chen, L., and Ma, X. (2020). Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2019.115254"},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Sasaki, Y., Tokuhara, H., Ohba, Y., Okabe, A., Nakayama, M., Nakagawa, H., Skene, R., Hoffman, I., Zou, H., and Yoshida, M. (2020). Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.126963"},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Lu, K., Wu, W., Zhang, C., Liu, Z., Xiao, B., Yuan, Z., Li, A., Chen, D., Zhai, X., and Jiang, Y. (2020). Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1\/2 inhibitors. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.127225"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1021\/acs.jmedchem.0c00055","article-title":"Identification of","volume":"63","author":"Zhu","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"111918","DOI":"10.1016\/j.ejmech.2019.111918","article-title":"Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK)","volume":"187","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus Kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1039\/D0MD00227E","article-title":"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold","volume":"11","author":"Baillache","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.bmcl.2014.03.075","article-title":"Syk inhibitors with high potency in presence of blood","volume":"24","author":"Thoma","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"113039","DOI":"10.1016\/j.ejmech.2020.113039","article-title":"Synthesis and anticancer activity evaluation of naphthalene-substituted triazole spirodienones","volume":"213","author":"Luo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"14921","DOI":"10.1021\/acs.jmedchem.0c01488","article-title":"N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1039\/D0MD00074D","article-title":"2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase","volume":"11","author":"Matheson","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"112934","DOI":"10.1016\/j.ejmech.2020.112934","article-title":"Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2\/3 and aurora A\/B kinases multi-targeted inhibitors","volume":"209","author":"Zheng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1039\/D0MD00436G","article-title":"Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives","volume":"12","author":"Sanachai","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1021\/acs.jmedchem.1c00713","article-title":"Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"113394","DOI":"10.1016\/j.ejmech.2021.113394","article-title":"Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2","volume":"218","author":"Xu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"113393","DOI":"10.1016\/j.ejmech.2021.113393","article-title":"Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor","volume":"219","author":"Rao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm800984v","article-title":"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity","volume":"52","author":"Howard","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1021\/jm8012129","article-title":"Discovery and development of aurora kinase inhibitors as anticancer agents","volume":"52","author":"Pollard","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1021\/acs.jmedchem.1c01137","article-title":"Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2\/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of Novel Pyrrolo[2,3-","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/acs.jmedchem.1c01765","article-title":"Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism","volume":"65","author":"Wellaway","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1039\/D2MD00153E","article-title":"Structure-based discovery of potent inhibitors of Axl: Design, synthesis, and biological evaluation","volume":"13","author":"Wu","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Mao, W., Wu, H., Guo, Q., Zheng, X., Wei, C., Liao, Y., Shen, L., Mi, J., Li, J., and Chen, S. (2022). Synthesis and evaluation of hydrazinyl-containing pyrrolo[2,3-d]pyrimidine series as potent, selective and oral JAK1 inhibitors for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett., 74.","DOI":"10.1016\/j.bmcl.2022.128905"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejmech.2017.08.009","article-title":"An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds","volume":"142","author":"Cascioferro","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"113781","DOI":"10.1016\/j.ejmech.2021.113781","article-title":"Pyrazolopyrimidines as anticancer agents: A review on structural and target-based approaches","volume":"225","author":"Asati","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"113768","DOI":"10.1016\/j.ejmech.2021.113768","article-title":"Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy","volume":"225","author":"Soltan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1016\/j.bmc.2017.07.043","article-title":"Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors","volume":"25","author":"Yamagishi","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.bmcl.2009.04.138","article-title":"Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening","volume":"19","author":"Kiss","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.bmcl.2009.04.039","article-title":"Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses","volume":"19","author":"Wilson","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1016\/j.bmcl.2009.10.054","article-title":"Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors","volume":"19","author":"Ioannidis","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.bmcl.2009.10.053","article-title":"2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2","volume":"19","author":"Ledeboer","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bmcl.2009.11.021","article-title":"A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors","volume":"20","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1016\/S0960-894X(03)00655-3","article-title":"Potent Quinoxaline-Based Inhibitors of PDGF Receptor Tyrosine Kinase Activity. Part 2: The Synthesis and Biological Activities of RPR127963, an Orally Bioavailable Inhibitor","volume":"13","author":"Wei","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"13259","DOI":"10.1021\/acs.jmedchem.0c01579","article-title":"Discovery of a Potent Dual SLK\/STK10 Inhibitor Based on a Maleimide Scaffold","volume":"64","author":"Serafim","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.bmcl.2008.03.057","article-title":"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor","volume":"18","author":"Ruel","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.bmcl.2008.03.019","article-title":"Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38 alpha inhibitors","volume":"18","author":"Das","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1021\/jm051106d","article-title":"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor","volume":"49","author":"Bhide","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1021\/jm060347y","article-title":"Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2","volume":"49","author":"Borzilleri","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1021\/jm0503594","article-title":"5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase","volume":"48","author":"Liu","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.bmc.2017.02.030","article-title":"Novel pyrrolopyrimidines as Mps1\/TTK kinase inhibitors for breast cancer","volume":"25","author":"Sugimoto","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Poli, G., Seidel, T., and Langer, T. (2018). Conformational Sampling of Small Molecules With iCon: Performance Assessment in Comparison With OMEGA. Front. Chem., 6.","DOI":"10.3389\/fchem.2018.00229"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","article-title":"Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6","volume":"400","author":"Chrencik","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/prot.22889","article-title":"A new regulatory switch in a JAK protein kinase","volume":"79","author":"Tsui","year":"2011","journal-title":"Proteins"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:33:50Z","timestamp":1760031230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":316,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["molecules30102183"],"URL":"https:\/\/doi.org\/10.3390\/molecules30102183","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}